Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib + Letrozole in Advanced Breast Cancer
NCT00880009Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jul 2009
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of bosutinib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival (Independent Radiologist). Started Jul 2009; status: terminated.
02
Drugs
bosutinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00880009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00880009.